ORGO - Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst

2024-06-10 03:57:48 ET

Summary

• Organogenesis has two disproportionate segments, with Surgical and Sports Medicine making up a small portion of revenues.
• The company's pipeline candidate, ReNu, has the potential to boost Surgical and Sports Medicine revenues.
• In recent years, Organogenesis has generated inconsistent earnings and may not need to raise cash before launching ReNu.

This is my third Organogenesis ( ORGO ) article, following most recently 07/2023's "Organogenesis: Solid Revenue Generation From A Hyper-Trading Wound Care Company". At the time, it traded at $4.31; I rated it a "Hold". As I write on 06/06/2024 its intervening trading range has been truly hyper as shown below:

For further details see: